Study of the Effectiveness of Ozurdex for the Control of Uveitis

PHASE4CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

January 31, 2014

Primary Completion Date

June 30, 2018

Study Completion Date

June 30, 2018

Conditions
Uveitis, IntermediateUveitis, Posterior
Interventions
DRUG

Dexamethasone pellet

"Dexamethasone pellet placement occurs within 14 days of baseline examination; for patients with bilaterally active uveitis, placement of a dexamethasone pellet in the second eye should occur within 14 days of the first implantation or within 30 day of the baseline examination.~Repeated placement is permitted every 3 months based on the best clinical judgment of the doctor and the study protocol."

Trial Locations (1)

21287

The Wilmer Eye Institute, Johns Hopkins Hospital, Baltimore

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Allergan

INDUSTRY

lead

Johns Hopkins University

OTHER